Announced today that Northwestern University has enrolled the first patient in the pivotal Phase III ...
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase...
Announced today its year-end 2024 update on operations following the filing of its audited Financial ...
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...
Announced today the publication of research in the Journal of the American College of Cardiology: Basic ...
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureToronto, Ontario--(Newsfile...
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing...
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase...
Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...